@article{Alotaibi_N-2022_89243,
title = {In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid},
author = {Alotaibi, N. and Alroomi, M. and Aboelhassan, W. and Hussein, S. and Rajan, R. and AlNasrallah, N. and Al Saleh, M. and Ramadhan, M. and Zhanna, K. and Pan, J. and Malhas, H. and Abdelnaby, H. and Almutairi, F. and Al-Bader, B. and Alsaber, A. and Abdullah, M.},
month = {jun},
year = {2022},
abstract = {Objective To investigate COVID-19 related mоrtаlity according to the use of corticosteroid therapy. Design Retrospective cohort study. Setting Two tertiary hospitals in Kuwait. Participants Overall, 962 patients with confirmed SARS-CoV-2 infection, were stratified according to whether they were treated with corticosteroids (dexamethasone or methylprednisolone). The mean age of the patients was 50.2 ± 15.9 years and 344/962 (35.9%) were female. Main outcome measures In-hospital mortality and cumulative all-cause mortality. Results Compared to non-corticosteroid therapy patients, corticosteroid therapy patients had a higher prevalence of hypertension, diabetes mellitus, cardiovascular disease, chronic lung disease, and chronic kidney disease; a longer hospital stay (median [IQR]: 17.0 [5.0–57.3] days vs 14.0 [2.0–50.2] days); and a higher in-hospital mortality (51/199 [25.6%] vs 36/763 [4.7%]). Logistic regression analysis showed a higher in-hospital mortality in the corticosteroid group (adjusted odds ratio [aOR]: 4.57, 95% confidence interval [CI]: 2.64–8.02, p &lt; 0.001). Cox proportional hazards regression showed that corticosteroid use was a significant predictor of mortality (hazard ratio [HR]: 3.96, p &lt; 0.001). Conclusions In-hospital mortality in patients with SARS-CoV-2 on corticosteroid therapy was 4.6 times higher than in those without corticosteroid therapy.},
journal = {Annals of Medicine and Surgery},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.amsu.2022.104105},
}
